Multi-Action Coatings – Straightforward Solutions for Complex Challenges

Medical devices face complex biocompatible challenges when innovating modern therapies. Multi-action coatings confront these complex challenges in one straightforward, high-performance technology which enhances device performance and improves patient well-being.

BioInteractions have developed three unique polymer coatings to help with these challenges:

Astute®Anti-thrombogenic Coating

Active-Endothelial Action

Astute® uses an active anti-thrombogenic agent bound within its polymer backbone in combination with passive components to block thrombus formation, mimic endothelial layer and reduce further risks to the patient.


Astute® Active-Endothelial Action:

  • Actively stops blood activation
  • Prevents protein and cellular deposition
  • Non-leaching and stable for long-term applications

AvertPlus™ Antimicrobial Coating

Long lasting, Contact-Kill Mechanism

AvertPlus™ reduces device related infections and targets biofilm formation through a contact-kill mechanism paired with passive components. This non-leaching combination instantly kills bacteria without the use of toxic components, protects the device surface from bacteria and consistently reduces infection in patients.


AvertPlus™ Long lasting, Contact Kill Mechanism:

  • Actively disrupt broad-spectrum of bacteria to result in lysis
  • Prevents deposition and adhesion of proteins
  • Non-leaching, non-toxic components for long term applications

Assist™ Hydrophilic Coating

Flexible and Durable Assistance

Assist™ significantly reduces friction and minimises obstacles faced at the device-body interface. The highly hydrophilic surface improves insertion and removal of devices, enhances surface smoothness to reduce adhesion and shields the device from deposition.


Assist™ Enhanced Lubricity:

  • Significantly reduces friction and shields the surface
  • Flexible, non-cytotoxic and stable for long term applications
  • Available as UV Cured or Heat Cured for application on various shapes and materials

Your All-In-One Coating Partner

BioInteractions manufactures all our coating technology in-house and supports our customers efforts with our customer focused Commitment to Care (C2C) services. Our high-performance, multi-action coating technology offers our partners the ability to confront complex biocompatible challenges with a straightforward solution and enhance the performance of their device.


Our expertise has been collected in our C2C services to supports partners’ through their development process. These services consider the challenges with the application of the coating onto the device, the data required for regulatory submission as well as coating services for commercial devices.


We combine high-performance, multi-action technology with customer focused services to ensure the highest quality coated devices are supplied to patients and to help our partners have confidence in our support in their innovation of enhanced devices. We are committed to maintain our quality throughout our high-performance, multi-action coating technology as well as customer focused support services to enable patients to access breakthrough therapies with the highest quality of coated devices.

Back To Top 

Go to article: Home | What’s in a nose?Go to article: In This IssueGo to article: Formacoat Company InsightGo to article: FormacoatGo to article: ContentsGo to article: Sandvik Company InsightGo to article: Sandvik Go to article: NewsGo to article: Coronavirus Executive BriefingGo to article: Can wearable devices be used to predict Covid-19?Go to article: Ten million Covid-19 antibody tests will strengthen UK’s testing strategyGo to article: Research Collective Company Insight Go to article: Research CollectiveGo to article: Covid-19 study in monkeys gives insight into possible immunityGo to article: Lack of protective equipment preparation led to spike in frontline healthcare worker deathsGo to article: Tricor SystemsGo to article: Mi3 Medical IntelligenceGo to article: Covid-19 pandemic urges a sudden spike in ventilator productionGo to article: Medicoat Go to article: The medical industry briefingGo to article: Elkem Company Insight Go to article: ElkemGo to article: The shocking truth: the rise and fall of electrical aversion therapyGo to article: BioInteractions Company Insight Go to article: BioInteractions Go to article: Review Display SystemsGo to article: The difficulty of deploying a Covid-19 home testing kitGo to article: device25Go to article: Regulatory Globe Company Insight Go to article: Regulatory GlobeGo to article: Accuracy and immunity: the ethics of Covid-19 home testingGo to article: ICF MercantileGo to article: Setting an example: Rwanda as a digital health success storyGo to article: SartoriusGo to article: Q&A: inside the ambulance of the future with O&H Vehicle TechnologyGo to article: mdi ConsultantsGo to article: Expert explainer: is it possible to smell Parkinson’s disease?Go to article: AccumoldGo to article: Are ‘smart’ bandages the future of wound care? Go to article: Micro Systems TechnologiesGo to article: Eye on the prize: ophthalmology’s digital futureGo to article: Proportion-AirGo to article: Will an artificial pancreas be a gamechanger for type 1 diabetes?Go to article: Electronic Sensor TechnologyGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2 ) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: ESMAGo to article: EventsGo to article: Next Issue